» Authors » Masami Iwasa

Masami Iwasa

Explore the profile of Masami Iwasa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 138
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Nakamura S, Kagawa K, Sumitani R, Uemura M, Takahashi M, Iwasa M, et al.
Intern Med . 2017 Aug; 56(15):2043-2047. PMID: 28768978
Primary superior vena cava lymphoma originating from the endothelium of a large vein is very rare. A 70-year-old man was admitted to the hospital; computed tomography showed a tumor limited...
12.
Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, et al.
Br J Haematol . 2016 Oct; 180(4):581-585. PMID: 27748523
No abstract available.
13.
Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, et al.
Oncotarget . 2016 Oct; 7(48):79064-79075. PMID: 27738323
Panobinostat, a pan-deacetylase inhibitor, synergistically elicits cytotoxic activity against myeloma (MM) cells in combination with the proteasome inhibitor bortezomib. Because precise mechanisms for panobinostat's anti-MM action still remain elusive, we...
14.
Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, et al.
Oncotarget . 2016 Sep; 7(43):70447-70461. PMID: 27626482
Myeloma (MM) cells and osteoclasts are mutually interacted to enhance MM growth while creating acidic bone lesions. Here, we explored acid sensing of MM cells and its role in MM...
15.
Yamashita M, Fujii Y, Ozaki K, Urano Y, Iwasa M, Nakamura S, et al.
Diagn Pathol . 2015 Oct; 10:185. PMID: 26449225
Malignant syphilis or lues maligna is a severe form of secondary syphilis that was commonly reported in the pre-antibiotic era, and has now reemerged with the advent of the human...
16.
Harada T, Ozaki S, Oda A, Tsuji D, Ikegame A, Iwasa M, et al.
PLoS One . 2014 Jan; 8(12):e83905. PMID: 24386306
The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in...